Rheumatoid Arthritis Drug Discoveries: what the future holds

Table of Contents

• INTRODUCTION
• WHAT IS RHEUMATOID ARTHRITIS?
  • Pathogenesis Of Rheumatoid Arthritis
  • Classification Of Rheumatoid Arthritis
  • Assessment Of Disease Activity And Response To Treatment
• CURRENT TREATMENT OPTIONS
  • Diagnosis of Rheumatoid Arthritis
  • Pharmacological Therapy
  • Treatment Strategies
• PATIENT STATISTICS
  • Incidence and Prevalence
  • The Future
• THE RHEUMATOID ARTHRITIS MARKET
  • PLAYERS AND PRODUCTS
    • Players And Products In 2007
    • Players And Products In 2015
  • DRUG GROWTH DRIVERS AND DAMPENERS
• ANALYSIS OF CURRENT LEADING PRODUCTS
  • NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
    • Celebrex
    • Arcoxia
    • Mobic
  • GLUCOCORTICOIDS
  • TRADITIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
  • BIOLOGICAL AGENTS
    • TNF Inhibitors
      • Remicade
      • Humira
      • Enbrel
    • Interleukin-1 Receptor Inhibitor
      • Kineret
    • B-Cell Targeted Therapy
      • Rituxan/MabThera
    • T-Cell Co-Stimulation Modulator
      • Orencia
• RESEARCH AND DEVELOPMENT OF RHEUMATOID ARTHRITIS DRUGS
  • LATE-PHASE PROJECTS
    • TNF Inhibitors
      • Cimzia
      • Golimumab
    • Interleukin-6 Receptor Inhibitor
      • Actemra
    • Interleukin-1 Receptor Inhibitor
      • Canakinumab
    • B-Cell Targeted Therapy
      • Ocrelizumab
      • Ofatumumab
    • Non-Steroidal Anti-Inflammatory Drugs
      • Iguratimod
      • PN-400
    • Glucocorticoid
      • Lodotra
  • PHASE II PROJECTS
  • Oral Therapies
    • Adenosine Receptor Antagonist
      • CF101
    • Cathepsin-S Inhibitor
      • RWJ-445380
    • Chemokine Receptor Antagonists
      • Selzentry
    • DHODH Inhibitor
      • SC12267
    • Interleukin Inhibitors
      • Apilimod
    • Kinase Inhibitors
      • 681323
      • 856553
      • BMS-582949
      • CP-195543
      • CP-690550
      • INCB18424
      • PH-797804
      • SCIO-469
      • Tamatinib
      • VX-702
    • T-Cell Co-Stimulation Modulator
      • RhuDex
    • Other Oral Therapies
      • 274150
      • CH-1504
      • CRx-102
      • K-832
      • PMI-001
      • R7277
  • Injectable Therapies
    • B-Cell Targeted Therapy
      • Atacicept
      • LymphoStat-B
      • TRU-015
    • Interleukin Inhibitors
      • AMG 108
    • Lymphotoxin Beta and LIGHT Pathway Inhibitor
      • Baminercept
    • RANK Ligand Inhibitor
      • Denosumab
    • TNF Inhibitor
      • tgAAC94
    • Other Injectable Therapies
      • MM-093
  • PHASEI PROJECTS
    • Kinase Inhibitors
      • ARRY-438162
      • ARRY-797
      • MLN0415
    • Anti-TNF
      • ART621
    • Others
      • PRTX-100
      • VAP-1
• APPENDIX 1: COMPETITOR RATIO ANALYSIS
• APPENDIX 2: COMPANY PROFILES
  • 4SC
  • Abbott
  • Amgen
  • Arana Therapeutics
  • AstraZeneca
  • Biogen Idec
  • Bristol-Myers Squibb
  • Can-Fite Biopharma
  • Chelsea Therapeutics
  • Chugai
  • CombinatoRx
  • Dainippon Sumitomo Pharma
  • Eisai
  • Eli Lilly
  • Genmab
  • GlaxoSmithKline
  • Human Genome Sciences
  • Johnson & Johnson
  • Kowa Pharmaceutical
  • Medarex
  • Medigene
  • Merck KGaA
  • Merrimack Pharmaceuticals
  • Millennium Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Novartis
  • Phytomedics
  • Pozen
  • Pfizer
  • Rigel Pharmaceuticals
  • Roche
  • sanofi-aventis
  • Schering-Plough
  • Synta Pharmaceuticals
  • Takeda
  • Targeted Genetics
  • Toyama Chemical
  • Trubion
  • Wyeth
  • Vertex Pharmaceuticals
• APPENDIX 3: GLOSSARY
• APPENDIX 4: SOURCES
• APPENDIX 5: PRODUCT INDEX

INDEX OF TABLES

• Traditional DMARDs used in the treatment of RA
• ACR responses
• Products In Development For The Treatment Of Rheumatoid Arthritis
• Competitor Ratio Analysis Scores
• Six- and 12-month ACR responses for RAPID 1
• Six and 12 month mean mTSS changes from baseline for RAPID 1
• Competitor Ratio Analysis Scores
• Competitor Ratio Analysis Summary

INDEX OF CHARTS

• Synovitis And Joint Destruction In Rheumatoid Arthritis
• Bone Erosion In Untreated Rheumatoid Arthritis
• Current Views On The Pathogenesis Of Rheumatoid Arthritis
• Guidelines For The Management Of Rheumatoid Arthritis
• Global Rheumatoid Arthritis Drug Sales (2007E)
• Rheumatoid Arthritis Market (2007E-2015E)
• Global Market Share of Major Biologic RA Products (2007E)
• Global Market Share Of RA Biologics And Oral Therapies By Sales (2015E)
• Celebrex RA Sales (2008E-2015E)
• Remicade RA Sales (2008E-2015E)
• Humira RA Sales (2008E-2015E)
• Enbrel RA Sales (2008E-2015E)
• Kineret RA Sales (2008E-2015E)
• Rituxan/MabThera RA Sales (2008E-2015E)
• Orencia RA Sales (2008E-2015E)
• Launch Of Biologics In Late-Phase Development To Treat Rheumatoid Arthritis
• Cimzia RA Sales (2008E-2015E)
• Golimumab RA Sales (2009E-2015E)
• The Role Of IL-6 In Inflammation
• Actemra RA Sales (2008E-2015E)
• Ocrelizumab RA sales (2011E-2015E)
• Ofatumumab RA Sales (2010E-2015E)
• CF101 RA Sales (2012E-2015E)
• SC12267 RA Sales (2011E-2015E)
• CP-195543 RA Sales (2012E-2015E)
• CP-690550 RA Sales (2011E-2015E)
• Scio-469 RA Sales (2012E-2015E)
• R788 RA Sales (2011E-2015E)
• RhuDex RA Sales (2012E-2015E)
• Atacicept RA Sales (2011E-2015E)
• LymphoStat-B RA sales (2011E-2015E)
• TRU-015 RA Sales (2011E-2015E)
• AMG 108 RA Sales (2011E-2015E)
• Baminercept RA Sales (2010E-2015E)
• Denosumab RA Sales (2009E-2015E)